Baseline characteristics of patients with an available HOMA-IR assessment versus the overall ITT population
| Patients with HOMA-IR assessment, n=147 | Total population, n=161 | |
| Male, n (%) | 74 (50) | 80 (50) |
| Age (years), mean (SD) | 44 (10) | 44 (10) |
| Caucasian, n (%) | 133 (90) | 145 (90) |
| BMI (kg/m2), mean (SD) | 25 (4.4) | 25 (4.3) |
| ALT (IU/ml), mean (SD) | 88 (65) | 89 (66) |
| Baseline log10 HCV RNA (IU/ml), mean (SD) | 6.5 (0.6) | 6.5 (0.6) |
| Extensive fibrosis* (F3–4), n (%) | 38 (26) | 41 (25) |
| Planned treatment arm, n (%) | ||
| q12h; α2a | 34 (23) | 40 (25) |
| q12h; α2b | 38 (26) | 39 (24) |
| q8h; α2a | 37 (25) | 40 (25) |
| q8h; α2b | 38 (26) | 42 (26) |
| SVR, n (%) | 121 (82) | 133 (83) |
↵* Four patients in the total ITT population had cirrhosis and were enrolled in the C208 trial in error, but allowed to continue.14 One patient from the subset of patients with available HOMA-IR data had cirrhosis.
α2a, peginterferon α2a/ribavirin; α2b, peginterferon α2a/ribavirin; ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; HOMA-IR, homoeostatic model assessment-insulin resistance; q8h, every 8 h; q12h, every 12 h; SVR, sustained virological response; ITT, intent-to-treat.